A study led by Masafumi Ikeda, National Cancer Center Hospita, Kashiwanoha, Kashiwa Chiba, Japan, and published in the Journal of Vascular and Interventional Radiology, has investigated transcatheter arterial chemoembolization (TACE) with emulsion of lipidol and anthracycline agent and gelatin sponge particles for hepatocellular carcinoma.
Siddharth A Padia, University of Washington Medical Center, Seattle, USA, and colleagues, stated that, although transarterial chemoembolization is a standard treatment for hepatocellular carcinoma, “wide variability in techniques has led to varying practices and results across institutions.”
Terumo Interventional Systems, a business unit of Terumo Medical Corporation, today announced the launch of a new, dedicated group focused on direct sales, marketing, support and distribution of key products to the urological specialty beginning April 1, 2013.
Covidien announced on 20 February 2013 the completion of patient enrolment in its iliac stent clinical study series. The series is composed of two prospective, multinational, multicentre studies—VISIBILITY Iliac and DURABILITY Iliac.
Sirtex Medical Limited (ASX: SRX) today announced half year results that demonstrate another strong financial performance over the reporting period and continued dose sales growth of its SIRSpheres ® microspheres targeted radiotherapy treatment for liver cancers.
Terumo Medical Corporation (Terumo), today announced that it has filed a patent infringement lawsuit against Vascular Solutions Inc. and Lepu Medical Technology (Beijing) Co., Ltd in the U.S. District Court of New Jersey.
Anne Roberts, UCSD Thornton Hospital, La Jolla, San Diego, USA, spoke to delegates at the International Symposium on Endovascular Therapy (ISET), 18–23 January 2013, Miami, Florida, USA, on the topic of indications for retrieval inferior vena cava filters, retrievable rates and contemporary issues which accompany filter implementation.
On the 27 February 2013, Toshiba announced that it would be showcased at the European Society of Radiology’s (ECR) Annual Meeting (7–11 March 2013, Vienna, Austria). The Aquilion ONE/ ViSION Edition is said by the company to have faster rotation speed of just 0.275 seconds which is applicable for all routine applications. A wider 78 cm gantry bore improves patient comfort and access. In combination with AIDR 3D, the ViSION Edition provides fast and robust low dose imaging for all patient examinations with negligible impact of reconstruction time, according Toshiba.
Los pacientes de diabetes que toman la clase más nueva de medicamentos para controlar los niveles de azúcar en la sangre tienen el doble de probabilidades de sufrir de pancreatitis que los que toman otros medicamentos para controlar el azúcar
Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced CE Mark approval for its Surefire Infusion System ST/LT and Surefire Specialty Catheters. The company will launch its latest line of microcatheters and specialty catheters for the interventional radiology and interventional oncology markets in Europe during the second quarter 2013, and immediately in New Zealand, where regulatory approval has also been granted
BSD Medical Corporation (BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today a 319% increase in sales of its MicroThermX® Microwave Ablation System (MicroThermX®) disposable SynchroWave antennas during the first five months of fiscal 2013, when compared to the first five months of fiscal 2012 sales of its SynchroWave antennas. BSD President Harold Wolcott stated, “This increase in sales of disposable antennas is indicative of the growing acceptance and use of MicroThermX® products in the ablation market
PneumRx, Inc., a leader in interventional pulmonology, announced the first U.S. patients treated with PneumRxs Lung Volume Reduction Coils (LVRCs) for severe emphysema. Dr. Charlie Strange, of the Medical University of South Carolina, and Dr. Frank Sciurba, of the University of Pittsburgh and UPMC, treated the first US patients in the FDA-approved RENEW Study. The RePneu® LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life for this underserved patient population
The Spectranetics Corporation (SPNC) today announced final results from the PATENT (Photo-Ablation using the TURBO-Booster(R) and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg. ISR occurs as a result of narrowing of the artery in patients who have undergone stenting for the treatment of peripheral arterial disease (PAD). There is currently no FDA-cleared or approved device to treat peripheral in-stent restenosis, which remains a major unsolved medical problem
Pregnant women who develop iliofemoral deep vein thrombosis often forgo the most effective treatment for fear of harming the baby. Yet treatment to remove the clot is not only safe, it can prevent serious problems, and death, suggests research presented at the International Symposium on Endovascular Therapy (ISET), 19–23 January 2013, Miami, Flordia, USA.
Munich Study Concludes 15 Year Outcome Data May Warrant Closing of Investigational Phase for HIFU
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos